Lantheus presents data on piflufolastat F 18 at 2023 ASCO symposium

Lantheus presented piflufolastat F 18 data at the 2023 American Society of Clinical Oncology, ASCO, Genitourinary Cancers Symposium, taking place February 16-18, 2023, in San Francisco, CA. Piflufolastat F 18 is a PSMA-targeted radiopharmaceutical approved in the US for imaging prostate cancer patients both at the time of initial staging and at disease recurrence. In this study, researchers sought to evaluate the clinical utility of piflufolastat F 18 scanning in men with very low/low PSA levels. "We had observed in the CONDOR Phase 3 study of men with biochemically recurrent prostate cancer, that nearly two-thirds of patients had their treatment plan altered, attributed to learnings from the scan itself," said Jean-Claude Provost, MD, Chief Medical Officer, Lantheus. "These data in the subset of men with low PSA levels reinforces the impact and potential role of piflufolastat F 18 in informing patient management decisions in real-world scenarios." A summary of the data presented follows: In patients with PSA levels below 0.5 ng/mL, changes in intended management occurred in 39.1 percent of cases. In 74.1 percent of patients with a reported change in management, the initial intended treatment was intensified as a result of the scan images. This analysis supports the clinical utility of piflufolastat F18 PET/CT in men with low PSA levels